Brady Todd R. 4

4 · Contineum Therapeutics, Inc. · Filed Jun 26, 2026

AI-generated summary of this filing

Updated Jun 26, 2026

Contineum (CTNM) Director Todd R. Brady Receives 19,000-Share Option Award

What Happened

Todd R. Brady, a non-employee director of Contineum Therapeutics, was granted a derivative award (stock option) covering 19,000 shares on 2026-06-26. The Form 4 reports an acquisition at $0.00, indicating an option grant rather than a cash purchase or share sale. No cash changed hands and no shares were sold.

Key Details

Transaction date: 2026-06-26. Transaction type/code: A (award/grant — derivative option).
Amount: options for 19,000 shares; reported acquisition price: $0.00 (reflects grant).
Vesting: Options vest in full on the earlier of (i) June 26, 2027 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, subject to continuous service (per footnote).
Shares owned after transaction: not specified in the filing.
Timeliness: Filing dated 2026-06-26 for the 2026-06-26 transaction — appears timely.

Context

This is a routine non-employee director compensation grant under Contineum’s 2024 Equity Incentive Plan and Non-Employee Director Compensation Program (automatic annual grant of 19,000-option awards to continuing directors). It is a grant of options (a derivative), not an exercise or sale — no immediate cash proceeds or market activity resulted from this filing.

Form 4

Period: 2026-06-26

Director

Transactions

Award
Stock Option (right to buy)
[F1]
2026-06-26+19,000→ 19,000 total
Exercise: $14.19Exp: 2036-06-25→ Class A Common Stock (19,000 underlying)

Footnotes (1)

[F1]Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Signature

/s/ Peter Slover, Attorney-in-Fact|2026-06-26

1 file